GlassScriptPhysician profile
Cesar M Pena
NPI 1295846723
$13,729.38
in general payments reported to CMS, 2019-2025
51 companies · $78.26 in 2025
The $78.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,930 · 2020: $2,243 · 2021: $3,456 · 2022: $2,882 · 2023: $2,121 · 2024: $19.70 · 2025: $78.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,119.42 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,686.09 | 2019-2023 | Ofev, Spiriva Respimat, Jardiance |
| Glaxosmithkline, LLC. | $1,562.20 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $655.37 | 2019-2023 | |
| Novo Nordisk INC | $645.06 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.06 | 2019-2023 | Trulance |
| Janssen Pharmaceuticals, INC | $435.23 | 2019-2022 | |
| Pfizer INC. | $363.75 | 2019-2023 | |
| Insmed, INC. | $355.34 | 2021-2023 | Arikayce |
| Allergan, INC. | $337.89 | 2019-2020 | |
| Advanced Respiratory, INC | $331.51 | 2020-2021 | |
| Mylan Specialty L.P. | $301.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $298.31 | 2019-2020 | |
| Lilly USA, LLC | $296.35 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $290.50 | 2019-2023 | Verquvo, Januvia |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.